All In Biotech

Drug Trial Radar · NCT01704781

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)

A Double-blind Placebo Controlled Immunogenicity Study of Vacc-4x + Lenalidomide Versus Vacc-4x With an Initial Open-label Dose Escalation Assessment of Lenalidomide in HIV-1-infected Subjects on Antiretroviral Therapy (ART).

Last checked: Nov 19, 2026Latest source record: Mar 8, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

36

Actual

Start

Sep 2012

Primary completion

Aug 2014

Study completion Aug 2014

Sponsor

Lead sponsor
Bionor Immuno ASIndustry
Sponsor type
Industry
Collaborators
Celgene Corporation
First posted
Oct 11, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Supportive care
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

During the course of HIV infection the number of CD4 cells decreases, resulting in a reduced immunological response and ultimately immune deficiency. Vacc-4x is a peptide-based HIV immunotherapy and the primary objective is to strengthen the immune system's response to HIV p24. By adding Lenalidomide, an immunomodulatory agent, as a supporting drug, it is anticipated that the effect of Vacc-4x might be enhanced.

Conditions

  • HIV-1 Infection

Interventions

  • LenalidomideDrug

    In Part A a dose escalation design is used (2,5; 5; 10; 25 mg). Part B will use the dose confirmed by Part A

  • Lenalidomide placeboDrug

    Capsules are identical to the active Lenalidomide capsules used.

  • Vacc-4XDrug

    Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.

  • rhuGM-CSFDrug

    Granulocyte macrophage colony stimulating factor as a local adjuvant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: To Establish Highest Tolerated Dose of Lenalidomide, Dose-Limiting ToxicityTime frame: 31 days
  2. Part A: To Establish Highest Tolerated Dose of Lenalidomide, CD4 Counts Over TimeTime frame: 31 days
  3. Part B: Change in CD4 CountTime frame: Week 26

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Klinik I für Innere Medizin Klinikum Der Universität zu Köln

    Cologne, Germany

  • University Medical Center Hamburg-Eppendorf

    Hamburg, Free and Hanseatic City of Hamburg, Germany

  • EIPMED - Gesellschaft fűr epidemiologische und klinische Forschung in der Medizin mbH Rubensstrasse 125

    Berlin, State of Berlin, Germany

  • Charite Campus, Virchow-Klinikum Medizinische Klinik mit Schwerpunkt Infektiologie Station 59 (Suedring 11) Augustenburger Platz 1

    Berlin, State of Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.